Fig. 7

GPR137 elevates AGS cell malignancy through Hippo signaling. A Protein expression examination of YAP (upper) and TAZ (lower) in YAP-shRNA or TAZ-shRNA transfected AGS cells. One representative of 3 independent blots is shown. B TEAD-luciferase assays in AGS cells transfected with GPR137 or an empty vector (control) in combination with YAP shRNA, TAZ shRNA, or YAP shRNA and TAZ shRNA for 72 h. **, ^##, p < 0.01; error bar, SD. N = 3. C CCK-8 assays in AGS cells transfected with GPR137 or an empty vector (control) in combination with YAP shRNA and TAZ shRNA at different periods. **p < 0.01; ^#p < 0.05; error bar, SD. N = 3. D Wound healing assays in AGS cells transfected with GPR137 or an empty vector (control) in combination with YAP shRNA and TAZ shRNA (GPR137 + shY/T). N = 3. E Quantitative analysis of (D). **, ^##, p < 0.01; error bar, SD. F Matrigel invasion assays in AGS cells transfected with GPR137 or an empty vector (control) in combination with YAP shRNA and TAZ shRNA (GPR137 + shY/T). N = 3. G Quantitative analysis of (F). **p < 0.01; ^#p < 0.05; error bar, SD. (H) Quantitative analysis for colony formation assays in AGS cells transfected with GPR137 or an empty vector (control) in combination with YAP shRNA and TAZ shRNA (GPR137 + shY/T). **p < 0.01; ^#p < 0.05; error bar, SD. N = 3